Portal:IEM/CoveredPathways

From WikiPathways

(Difference between revisions)
Jump to: navigation, search
Current revision (15:00, 9 November 2024) (view source)
 
(4 intermediate revisions not shown.)
Line 3: Line 3:
|-
|-
| 13 || Disorders of pyrimidine and purine metabolism || [https://www.wikipathways.org/index.php/Pathway:WP4225 WP4225] and [https://www.wikipathways.org/index.php/Pathway:WP4224 WP4224] || 41 || style="font-style: italic; color: blue;" | Approved (ed.5)
| 13 || Disorders of pyrimidine and purine metabolism || [https://www.wikipathways.org/index.php/Pathway:WP4225 WP4225] and [https://www.wikipathways.org/index.php/Pathway:WP4224 WP4224] || 41 || style="font-style: italic; color: blue;" | Approved (ed.5)
 +
|-
 +
| 14 || Disorders of Nucleotide Metabolism ||  ||  || style="font-style: italic; color: blue;" |
|-
|-
| 15 || Creatine disorders || [https://www.wikipathways.org/index.php/Pathway:WP5190 WP5190] || 32 || style="font-style: italic; color: blue;" | Approved
| 15 || Creatine disorders || [https://www.wikipathways.org/index.php/Pathway:WP5190 WP5190] || 32 || style="font-style: italic; color: blue;" | Approved
Line 10: Line 12:
| 17 || Disorders of ammonia detoxification || style="font-style: italic; color: red;" | [https://www.wikipathways.org/index.php/Pathway:WP4595 WP4595]  || 4 || style="font-style: italic; color: blue;" | Approved
| 17 || Disorders of ammonia detoxification || style="font-style: italic; color: red;" | [https://www.wikipathways.org/index.php/Pathway:WP4595 WP4595]  || 4 || style="font-style: italic; color: blue;" | Approved
|-
|-
-
| 18 || Disorders of amino acid transport || style="font-style: italic; color: red;" | [https://www.wikipathways.org/index.php/Pathway:WP5029 WP5029]  || 6 || style="font-style: italic; color: orange;" | In Progress
+
| 18 || Disorders of amino acid transport || style="font-style: italic; color: red;" | [https://www.wikipathways.org/index.php/Pathway:WP5029 WP5029]  || 6 || style="font-style: italic; color: blue;" | Approved
|-
|-
| 19 || Disorders of monoamine metabolism || [https://www.wikipathways.org/index.php/Pathway:WP4220 WP4220] || 31|| style="font-style: italic; color: blue;" | Approved (ed.5) || 6, non missing
| 19 || Disorders of monoamine metabolism || [https://www.wikipathways.org/index.php/Pathway:WP4220 WP4220] || 31|| style="font-style: italic; color: blue;" | Approved (ed.5) || 6, non missing
Line 27: Line 29:
|-
|-
| 26 || Disorders of glycine metabolism || Fig.5.2: [https://www.wikipathways.org/index.php/Pathway:WP4688 WP4688]  || 5|| style="font-style: italic; color: blue;" | Approved
| 26 || Disorders of glycine metabolism || Fig.5.2: [https://www.wikipathways.org/index.php/Pathway:WP4688 WP4688]  || 5|| style="font-style: italic; color: blue;" | Approved
 +
|-
 +
| 27 || Disorders of Lipoic Acid and Iron-Sulphur Protein Metabolism ||  ||  || style="font-style: italic; color: blue;" |
|-
|-
| 28 || Disorders of cobalamin metabolism || [https://www.wikipathways.org/index.php/Pathway:WP4271 WP4271] || 13|| style="font-style: italic; color: blue;" | Approved
| 28 || Disorders of cobalamin metabolism || [https://www.wikipathways.org/index.php/Pathway:WP4271 WP4271] || 13|| style="font-style: italic; color: blue;" | Approved
Line 38: Line 42:
|-
|-
| 32 || Disorders of riboflavin metabolism || [https://www.wikipathways.org/index.php/Pathway:WP5037 WP5037] || 16|| style="font-style: italic; color: blue;" | Approved
| 32 || Disorders of riboflavin metabolism || [https://www.wikipathways.org/index.php/Pathway:WP5037 WP5037] || 16|| style="font-style: italic; color: blue;" | Approved
 +
|-
 +
| 33 || Disorders of Niacin, NAD, and Pantothenate Metabolism ||  ||  || style="font-style: italic; color: blue;" |
|-
|-
| 34 || Vitamin B6 -Dependent and Responsive Disorders || [https://www.wikipathways.org/index.php/Pathway:WP4228 WP4228] || 11|| style="font-style: italic; color: blue;" | Approved (ed.5) || 5, non missing
| 34 || Vitamin B6 -Dependent and Responsive Disorders || [https://www.wikipathways.org/index.php/Pathway:WP4228 WP4228] || 11|| style="font-style: italic; color: blue;" | Approved (ed.5) || 5, non missing
Line 46: Line 52:
|-
|-
| 37 || Iron metabolism disorder || [https://www.wikipathways.org/index.php/Pathway:WP5172 WP5172] || 40 || style="font-style: italic; color: blue;" | Approved
| 37 || Iron metabolism disorder || [https://www.wikipathways.org/index.php/Pathway:WP5172 WP5172] || 40 || style="font-style: italic; color: blue;" | Approved
 +
|-
 +
| 38 || Disorders of Manganese Metabolism ||  ||  || style="font-style: italic; color: blue;" |
|-
|-
| 39 || Disorders of carbohydrate and glucose transport ||  Fig.18.3:[https://www.wikipathways.org/index.php/Pathway:WP5173 WP5173],  <br/> Fig.18.4: [https://www.wikipathways.org/index.php/Pathway:WP5178 WP5178]  || 18 || style="font-style: italic; color: blue;" | Approved
| 39 || Disorders of carbohydrate and glucose transport ||  Fig.18.3:[https://www.wikipathways.org/index.php/Pathway:WP5173 WP5173],  <br/> Fig.18.4: [https://www.wikipathways.org/index.php/Pathway:WP5178 WP5178]  || 18 || style="font-style: italic; color: blue;" | Approved
 +
|-
 +
| 40 || Disorders of Pentose Phosphate Pathway and Polyol Metabolism ||  ||  || style="font-style: italic; color: blue;" |
 +
|-
 +
| 41 || Disorders Congenital Hyperinsulinism ||  ||  || style="font-style: italic; color: blue;" |
|-
|-
| 42 || Disorders of pyruvate and Krebs cycle metabolism || [https://www.wikipathways.org/index.php/Pathway:WP4236 WP4236] || 20|| style="font-style: italic; color: blue;" | Approved
| 42 || Disorders of pyruvate and Krebs cycle metabolism || [https://www.wikipathways.org/index.php/Pathway:WP4236 WP4236] || 20|| style="font-style: italic; color: blue;" | Approved
 +
|-
 +
| 43 || Disorders of Mitochondrial Carriers ||  ||  || style="font-style: italic; color: blue;" |
 +
|-
 +
| 44 || Isolated Mitochondrial Complex Deficiencies ||  ||  || style="font-style: italic; color: blue;" |
 +
|-
 +
| 45 || Disorders of Replication, Transcription and Translation of Mitochondrial DNA ||  ||  || style="font-style: italic; color: blue;" |
 +
|-
 +
| 46 || Disorders of Mitochondrial Homeostatis, Dynamics, Protein Import, and Quality Control ||  ||  || style="font-style: italic; color: blue;" |
|-
|-
| 47 || Primary CoQ10 deficiencies || [https://www.wikipathways.org/index.php/Pathway:WP5037 WP5037] || 16|| style="font-style: italic; color: blue;" | Approved
| 47 || Primary CoQ10 deficiencies || [https://www.wikipathways.org/index.php/Pathway:WP5037 WP5037] || 16|| style="font-style: italic; color: blue;" | Approved
|-
|-
| 48 || Disorders of carnitine, fatty acid and fatty aldehyde metabolism || [https://www.wikipathways.org/index.php/Pathway:WP5123 WP5123] || 17 || style="font-style: italic; color: orange;" | In Progress
| 48 || Disorders of carnitine, fatty acid and fatty aldehyde metabolism || [https://www.wikipathways.org/index.php/Pathway:WP5123 WP5123] || 17 || style="font-style: italic; color: orange;" | In Progress
 +
|-
 +
| 49 || Disorders of Glycerol Metabolism ||  ||  || style="font-style: italic; color: blue;" |
|-
|-
| 50 || Disorders of ketone body metabolism || Fig.23.1 and 23.2:[https://www.wikipathways.org/index.php/Pathway:WP5175 WP5175],  <br/> Fig.23.3: [https://www.wikipathways.org/index.php/Pathway:WP5195 WP5195] || 23|| style="font-style: italic; color: blue;" | Approved
| 50 || Disorders of ketone body metabolism || Fig.23.1 and 23.2:[https://www.wikipathways.org/index.php/Pathway:WP5175 WP5175],  <br/> Fig.23.3: [https://www.wikipathways.org/index.php/Pathway:WP5195 WP5195] || 23|| style="font-style: italic; color: blue;" | Approved
 +
|-
 +
| 51 || Disorders of Complex Lipids ||  ||  || style="font-style: italic; color: blue;" |
|-
|-
| 52 || Disorders of eicosanoid metabolism (including leukotrienes) || [https://www.wikipathways.org/index.php/Pathway:WP5171 WP5171] || 38|| style="font-style: italic; color: blue;" | Approved
| 52 || Disorders of eicosanoid metabolism (including leukotrienes) || [https://www.wikipathways.org/index.php/Pathway:WP5171 WP5171] || 38|| style="font-style: italic; color: blue;" | Approved
Line 68: Line 92:
|-
|-
| 57 || Disorders of Heme metabolism || [https://www.wikipathways.org/index.php/Pathway:WP5169 WP5169] || 33 || style="font-style: italic; color: blue;" | Approved
| 57 || Disorders of Heme metabolism || [https://www.wikipathways.org/index.php/Pathway:WP5169 WP5169] || 33 || style="font-style: italic; color: blue;" | Approved
 +
|-
 +
| 58 || Inherited Disorders of Bilirubin Metabolite ||  ||  || style="font-style: italic; color: blue;" |
 +
|-
 +
| 59 || Disorders of Autophagy ||  ||  || style="font-style: italic; color: blue;" |
|-
|-
| 60 || Lysosomal storage disorders || [https://www.wikipathways.org/index.php/Pathway:WP4153 WP4153] || 25|| style="font-style: italic; color: blue;" | Approved (ed.5) || 8, 8 unconnected
| 60 || Lysosomal storage disorders || [https://www.wikipathways.org/index.php/Pathway:WP4153 WP4153] || 25|| style="font-style: italic; color: blue;" | Approved (ed.5) || 8, 8 unconnected
 +
|-
 +
| 61 || The Neuronal Ceroid Lipofuscinoses ||  ||  || || no pathway diagram
 +
|-
 +
| 62 || Mucolipidoses, Multiple Sulfatase Deficiency, and Cathepsin K and C Deficiency ||  ||  || style="font-style: italic; color: blue;" |
 +
|-
 +
| 63 || Oligosaccharidoses and Sialic Acid Disorders ||  ||  || style="font-style: italic; color: blue;" |
 +
|-
 +
| 64 || The Mucopolysaccharidoses ||  ||  || style="font-style: italic; color: blue;" |
|-
|-
| 65 || Disorders of oxalate metabolism || [https://www.wikipathways.org/index.php/Pathway:WP5166 WP5166] || 28 || style="font-style: italic; color: blue;" | Approved
| 65 || Disorders of oxalate metabolism || [https://www.wikipathways.org/index.php/Pathway:WP5166 WP5166] || 28 || style="font-style: italic; color: blue;" | Approved
|-
|-
| 66 || Congenital disorders of N-linked and O-linked glycosylation || [https://www.wikipathways.org/index.php/Pathway:WP4521 WP4521] || 30|| style="font-style: italic; color: blue;" | Approved
| 66 || Congenital disorders of N-linked and O-linked glycosylation || [https://www.wikipathways.org/index.php/Pathway:WP4521 WP4521] || 30|| style="font-style: italic; color: blue;" | Approved
 +
|-
 +
| 67 || Disorders of Oxalate Metabolism ||  ||  || style="font-style: italic; color: blue;" |
 +
|-
 +
| 68 || Congenital Disorders of Glycosylation ||  ||  || style="font-style: italic; color: blue;" |
|-
|-
| 69 || Cerebral organic acidurias || [https://www.wikipathways.org/index.php/Pathway:WP4519 WP4519] and [https://www.wikipathways.org/index.php/Pathway:WP5030 WP5030] || 8 & 9|| style="font-style: italic; color: blue;" | Approved
| 69 || Cerebral organic acidurias || [https://www.wikipathways.org/index.php/Pathway:WP4519 WP4519] and [https://www.wikipathways.org/index.php/Pathway:WP5030 WP5030] || 8 & 9|| style="font-style: italic; color: blue;" | Approved
 +
|-
 +
| 70 || 3-Methylglutaconic Acidurias ||  ||  || style="font-style: italic; color: blue;" |
|-
|-
| - || Disorders of phosphoinositide metabolism || [https://www.wikipathways.org/index.php/Pathway:WP4971 WP4971] || NA || style="font-style: italic; color: blue;" | Approved
| - || Disorders of phosphoinositide metabolism || [https://www.wikipathways.org/index.php/Pathway:WP4971 WP4971] || NA || style="font-style: italic; color: blue;" | Approved

Current revision

Chapter ed. 5 Title Links WP Chapter ed. 4 Status Diseases: x from ch. ed. 4
(+y) from other ch.
13 Disorders of pyrimidine and purine metabolism WP4225 and WP4224 41 Approved (ed.5)
14 Disorders of Nucleotide Metabolism
15 Creatine disorders WP5190 32 Approved
16 Disorders of glutathione metabolism WP4518 42 Approved
17 Disorders of ammonia detoxification WP4595 4 Approved
18 Disorders of amino acid transport WP5029 6 Approved
19 Disorders of monoamine metabolism WP4220 31 Approved (ed.5) 6, non missing
20 Disorders of phenylalanine and tetrahydrobiopterin metabolism WP4156 1 Approved (ed.5) 8 (+2), non missing
21 Disorders of tyrosine metabolism WP4506 2 Approved (ed.5) 5, non missing
22 Disorders of sulfur amino acid and sulfide metabolism WP4292 3 Approved 7, non missing
23 Disorders of branched-chain amino acid metabolism WP4686 7 Approved
24 Disorders of Beta and Gamma Amino Acids Fig.24.2: WP4157 5 (Fig.5.3) Approved (ed.5) 2, non missing
26 Disorders of glycine metabolism Fig.5.1:WP5028,
Fig.5.4: WP5026 		5 In Progress
26 Disorders of glycine metabolism Fig.5.2: WP4688 5 Approved
27 Disorders of Lipoic Acid and Iron-Sulphur Protein Metabolism
28 Disorders of cobalamin metabolism WP4271 13 Approved
29 Disorders of folate metabolism WP4259 and WP4288 10 Approved 9 (+3), non missing
30 Disorders of biotin metabolism WP5031 14 Approved
31 Disorders of thiamine metabolism WP4297 15 Approved
32 Disorders of riboflavin metabolism WP5037 16 Approved
33 Disorders of Niacin, NAD, and Pantothenate Metabolism
34 Vitamin B6 -Dependent and Responsive Disorders WP4228 11 Approved (ed.5) 5, non missing
35 Disorders of molybdenum metabolism WP4507 and WP4504 12 Approved
36 Disorders of copper , zinc and selenium metabolism WP5189 39 Approved
37 Iron metabolism disorder WP5172 40 Approved
38 Disorders of Manganese Metabolism
39 Disorders of carbohydrate and glucose transport Fig.18.3:WP5173,
Fig.18.4: WP5178 		18 Approved
40 Disorders of Pentose Phosphate Pathway and Polyol Metabolism
41 Disorders Congenital Hyperinsulinism
42 Disorders of pyruvate and Krebs cycle metabolism WP4236 20 Approved
43 Disorders of Mitochondrial Carriers
44 Isolated Mitochondrial Complex Deficiencies
45 Disorders of Replication, Transcription and Translation of Mitochondrial DNA
46 Disorders of Mitochondrial Homeostatis, Dynamics, Protein Import, and Quality Control
47 Primary CoQ10 deficiencies WP5037 16 Approved
48 Disorders of carnitine, fatty acid and fatty aldehyde metabolism WP5123 17 In Progress
49 Disorders of Glycerol Metabolism
50 Disorders of ketone body metabolism Fig.23.1 and 23.2:WP5175,
Fig.23.3: WP5195 		23 Approved
51 Disorders of Complex Lipids
52 Disorders of eicosanoid metabolism (including leukotrienes) WP5171 38 Approved
53 Disorders of lipoprotein metabolism WP4522 43 Approved
54 Cholesterol synthesis disorders WP5193 36 Approved
55 Disorders of steroid metabolism WP4523 and WP4524 37 Approved
56 Disorders of Bile acid synthesis (and biliary transport) WP5176 34 Approved
57 Disorders of Heme metabolism WP5169 33 Approved
58 Inherited Disorders of Bilirubin Metabolite
59 Disorders of Autophagy
60 Lysosomal storage disorders WP4153 25 Approved (ed.5) 8, 8 unconnected
61 The Neuronal Ceroid Lipofuscinoses no pathway diagram
62 Mucolipidoses, Multiple Sulfatase Deficiency, and Cathepsin K and C Deficiency
63 Oligosaccharidoses and Sialic Acid Disorders
64 The Mucopolysaccharidoses
65 Disorders of oxalate metabolism WP5166 28 Approved
66 Congenital disorders of N-linked and O-linked glycosylation WP4521 30 Approved
67 Disorders of Oxalate Metabolism
68 Congenital Disorders of Glycosylation
69 Cerebral organic acidurias WP4519 and WP5030 8 & 9 Approved
70 3-Methylglutaconic Acidurias
- Disorders of phosphoinositide metabolism WP4971 NA Approved
- Oxysterols derived from cholesterol WP4545 NA Approved
- Mitochondrial oxidative phosphorylation 22 In Progress


Information on Pathway Curation:

This Table provides an overview of which chapters have been covered by WikiPathways. Approved pathways are coloured blue; pathways which still need work (however are a part of the database) are coloured orange.


Tip:

Click on the arrows behind the Table headers to sort this table based on Chapter number (edition 4 and 5 available), title, WikiPathways reference and Curation Status.


Pathway Visualisations

View all digitized Pathways from the Physician's Guide to the Diagnosis, Treatment, and Follow-Up of Inherited Metabolic Diseases by Blau et al. (see it on Scholia.)


How to add a pathway to the portal

The list of Featured Pathways is not static and can be updated at any time. If you know of a pathway that should be added, please contact Denise Slenter.

Retrieved from "https://classic.wikipathways.org/index.php/Portal:IEM/CoveredPathways"
Personal tools